$RGBP
Regen BioPharma Inc Stock $rgbp

$rgbp Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000160706224000238 Filed on August 13, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue		$59.07K	$59.07K
YoY Change		-0.01%	88.77%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$134.5K	$99.22K
YoY Change		35.59%	14.61%
% of Gross Profit
Research & Development		$32.50K	$45.00K
YoY Change		-27.78%	44.88%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$32.50K	$144.2K
YoY Change		-77.46%	364.31%
Operating Profit		-$108.0K	-$85.16K
YoY Change		26.79%	44.55%
Interest Expense		-$22.15K	-$14.06K
YoY Change		57.54%	-146.25%
% of Operating Profit
Other Income/Expense, Net			$0.00
YoY Change
Pretax Income		-$130.1K	-$99.22K
YoY Change		31.14%	-100.15%
Income Tax
% Of Pretax Income
Net Earnings	-$264.9K	-$130.1K	-$99.22K
YoY Change	-18.5%	31.14%	-100.15%
Net Earnings / Revenue		-220.3%	-167.97%
Basic Earnings Per Share		-$0.03	-$0.03
Diluted Earnings Per Share		-$0.03	-$0.03
COMMON SHARES
Basic Shares Outstanding	4.508M shares	4.214M shares	3.381M shares
Diluted Shares Outstanding		4.214M shares	3.381M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$61.85K	$690.00
YoY Change		8863.77%	-99.38%
Cash & Equivalents	$716.00	$61.85K	$692.00
Short-Term Investments
Other Short-Term Assets		$23.42K	$5.380K
YoY Change		335.32%	-80.65%
Inventory
Prepaid Expenses			$377.00
Receivables	$94.87K	$67.15K	$56.55K
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$159.9K	$152.4K	$62.62K
YoY Change	22.01%	143.4%	-85.78%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$17.73K	$17.73K	$222.6K
YoY Change	-92.03%	-92.03%	-10.76%
Other Assets
YoY Change
Total Long-Term Assets	$17.73K	$17.73K	$222.6K
YoY Change	-92.03%	-92.03%	-10.76%
TOTAL ASSETS
Total Short-Term Assets	$159.9K	$152.4K	$62.62K
Total Long-Term Assets	$17.73K	$17.73K	$222.6K
Total Assets	$177.6K	$170.2K	$285.2K
YoY Change	-49.77%	-40.34%	-58.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$29.67K	$29.42K	$29.40K
YoY Change	-0.02%	0.05%	2.09%
Accrued Expenses		$1.662M	$1.630M
YoY Change		1.99%	-18.69%
Deferred Revenue
YoY Change
Short-Term Debt		$219.2K	$101.7K
YoY Change		115.54%	8169.11%
Long-Term Debt Due		$499.9K	$509.9K
YoY Change		-1.96%	-67.75%
Total Short-Term Liabilities	$5.372M	$5.328M	$5.314M
YoY Change	1.2%	0.26%	-41.21%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.372M	$5.328M	$5.314M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$5.372M	$5.328M	$5.314M
YoY Change	-1.58%	0.26%	-41.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$20.62M	-$20.35M	-$19.42M
YoY Change	4.39%	4.77%	-6.74%
Common Stock	$527.00	$25.33K	$339.00
YoY Change	49.72%	7370.8%	-99.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.194M	-$5.158M	-$5.029M
YoY Change
Total Liabilities & Shareholders Equity	$177.6K	$170.2K	$285.2K
YoY Change	-49.77%	-40.34%	-58.65%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$264.9K	-$130.1K	-$99.22K
YoY Change	-18.5%	31.14%	-100.15%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities		-$172.6K	-$87.01K
YoY Change		98.36%	-29.65%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		156.3K	0.000
YoY Change
NET CHANGE
Cash From Operating Activities		-172.6K	-87.01K
Cash From Investing Activities
Cash From Financing Activities		156.3K	0.000
Net Change In Cash		-16.26K	-87.01K
YoY Change		-81.31%	-29.65%
FREE CASH FLOW
Cash From Operating Activities		-$172.6K	-$87.01K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001589150
CY2023Q1	RGBP	Common Shares Issued Pursuant To Round Up Provision CommonSharesIssuedPursuantToRoundUpProvision		usd
CY2023Q1	RGBP	Preferred Shares Issued Pursuant To Round Up Provision PreferredSharesIssuedPursuantToRoundUpProvision		usd
CY2023Q1	RGBP	Preferred Shares Reverse Stock Split Value PreferredSharesReverseStockSplitValue		usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	REGEN BIOPHARMA, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-5192997
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4700 Spring Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	St 304
	dei	Entity Address City Or Town EntityAddressCityOrTown	La Mesa
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91942
	dei	City Area Code CityAreaCode	619
	dei	Local Phone Number LocalPhoneNumber	722-5505
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4508320	shares
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	us-gaap	Cash Cash	61849	usd
CY2023Q3	us-gaap	Cash Cash	121037	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	67147	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2023Q3	RGBP	Notes Receivable Related Party Current NotesReceivableRelatedPartyCurrent	0	usd
CY2024Q2	RGBP	Prepaid Expenses PrepaidExpenses	10921	usd
CY2023Q3	RGBP	Prepaid Expenses PrepaidExpenses	0	usd
CY2024Q2	us-gaap	Prepaid Rent PrepaidRent	12500	usd
CY2023Q3	us-gaap	Prepaid Rent PrepaidRent	10000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	152417	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	131037	usd
CY2024Q2	RGBP	Investment Securities Related Party InvestmentSecuritiesRelatedParty	17733	usd
CY2023Q3	RGBP	Investment Securities Related Party InvestmentSecuritiesRelatedParty	222580	usd
CY2024Q2	us-gaap	Other Assets OtherAssets	17733	usd
CY2023Q3	us-gaap	Other Assets OtherAssets	222580	usd
CY2024Q2	us-gaap	Assets Assets	170150	usd
CY2023Q3	us-gaap	Assets Assets	353617	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	29416	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	29674	usd
CY2024Q2	RGBP	Note Payable NotePayable	218230	usd
CY2023Q3	RGBP	Note Payable NotePayable	95710	usd
CY2024Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4241	usd
CY2023Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4241	usd
CY2024Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	359970	usd
CY2023Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	342588	usd
CY2024Q2	RGBP	Accounts Payables And Accrued Liabilities Current AccountsPayablesAndAccruedLiabilitiesCurrent	1256630	usd
CY2023Q3	RGBP	Accounts Payables And Accrued Liabilities Current AccountsPayablesAndAccruedLiabilitiesCurrent	1256630	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	41423	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	41423	usd
CY2024Q2	us-gaap	Bank Overdrafts BankOverdrafts	1000	usd
CY2023Q3	us-gaap	Bank Overdrafts BankOverdrafts	1000	usd
CY2024Q2	RGBP	Due To Investor DueToInvestor	20000	usd
CY2023Q3	RGBP	Due To Investor DueToInvestor	20000	usd
CY2024Q2	RGBP	Unearned Income UnearnedIncome	1496811	usd
CY2023Q3	RGBP	Unearned Income UnearnedIncome	1591731	usd
CY2024Q2	RGBP	Unearned Income Related Party UnearnedIncomeRelatedParty	0	usd
CY2023Q3	RGBP	Unearned Income Related Party UnearnedIncomeRelatedParty	15126	usd
CY2024Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	1400261	usd
CY2023Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	1400000	usd
CY2024Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	499880	usd
CY2023Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	499880	usd
CY2024Q2	RGBP	Convertible Notes Payable Related Parties Less Unamortized Discount ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount	0	usd
CY2023Q3	RGBP	Convertible Notes Payable Related Parties Less Unamortized Discount ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount	10000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5327862	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5308003	usd
CY2024Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2023Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	149614	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	149614	usd
CY2024Q2	us-gaap	Liabilities Liabilities	5327862	usd
CY2023Q3	us-gaap	Liabilities Liabilities	5457617	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5800000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4373078	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4373078	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3506366	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3506366	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	439	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	352	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	800000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	800000000	shares
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	14456692	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	13908141	usd
CY2024Q2	us-gaap	Other Additional Capital OtherAdditionalCapital	736326	usd
CY2023Q3	us-gaap	Other Additional Capital OtherAdditionalCapital	736326	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20351216	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19748863	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-5157712	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-5104000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	170150	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	353617	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31640	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31640	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	94920	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	94920	usd
CY2024Q2	RGBP	Revenues Related Party RevenuesRelatedParty	27425	usd
CY2023Q2	RGBP	Revenues Related Party RevenuesRelatedParty	27425	usd
	RGBP	Revenues Related Party RevenuesRelatedParty	82274	usd
	RGBP	Revenues Related Party RevenuesRelatedParty	82274	usd
CY2024Q2	us-gaap	Revenues Revenues	59065	usd
CY2023Q2	us-gaap	Revenues Revenues	59065	usd
	us-gaap	Revenues Revenues	177194	usd
	us-gaap	Revenues Revenues	177194	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32500	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45001	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	120161	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	176960	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16492	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9262	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38298	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	36660	usd
CY2024Q2	us-gaap	Professional Fees ProfessionalFees	95539	usd
CY2023Q2	us-gaap	Professional Fees ProfessionalFees	74957	usd
	us-gaap	Professional Fees ProfessionalFees	295839	usd
	us-gaap	Professional Fees ProfessionalFees	546437	usd
CY2024Q2	RGBP	Rental Expense RentalExpense	22500	usd
CY2023Q2	RGBP	Rental Expense RentalExpense	15000	usd
	RGBP	Rental Expense RentalExpense	54715	usd
	RGBP	Rental Expense RentalExpense	45000	usd
CY2024Q2	us-gaap	Costs And Expenses CostsAndExpenses	167031	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	144220	usd
	us-gaap	Costs And Expenses CostsAndExpenses	509012	usd
	us-gaap	Costs And Expenses CostsAndExpenses	805057	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-107966	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-85155	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-331819	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-627863	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	17554	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	14063	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	52382	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	43507	usd
CY2024Q2	RGBP	Interest Expense Attributable To Amortization Of Discount InterestExpenseAttributableToAmortizationOfDiscount	-4339	usd
CY2023Q2	RGBP	Interest Expense Attributable To Amortization Of Discount InterestExpenseAttributableToAmortizationOfDiscount	0	usd
	RGBP	Interest Expense Attributable To Amortization Of Discount InterestExpenseAttributableToAmortizationOfDiscount	-13045	usd
	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	-204847	usd
CY2024Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-261	usd
CY2023Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-261	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2151755	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1150	usd
CY2024Q2	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-22154	usd
CY2023Q2	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-14063	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-270534	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2109397	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-130120	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-99218	usd
	us-gaap	Net Income Loss NetIncomeLoss	-602353	usd
	us-gaap	Net Income Loss NetIncomeLoss	1481534	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-117108	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-99218	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-602353	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1303750	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.39
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.39
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4213611	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4213611	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3381366	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3381366	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3974434	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3974434	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3370012	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3370012	shares
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-5104000	usd
CY2023Q4	RGBP	Shares Issued For Cash SharesIssuedForCash	22726	usd
CY2023Q4	RGBP	Shares Issued For Cash2 SharesIssuedForCash2	46091	usd
CY2023Q4	RGBP	Shares Issued For Cash3 SharesIssuedForCash3	38205	usd
CY2023Q4	RGBP	Shares Issued For Cash4 SharesIssuedForCash4	32629	usd
CY2023Q4	RGBP	Shares Issued For Cash5 SharesIssuedForCash5	38101	usd
CY2023Q4	RGBP	Shares Issued For Cash6 SharesIssuedForCash6	34543	usd
CY2023Q4	us-gaap	Profit Loss ProfitLoss	-349760	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-5241463	usd
CY2024Q1	RGBP	Shares Issued For Cash7 SharesIssuedForCash7	39638	usd
CY2024Q1	RGBP	Shares Issued For Cash8 SharesIssuedForCash8	44297	usd
CY2024Q1	RGBP	Shares Issued For Cash9 SharesIssuedForCash9	19614	usd
CY2024Q1	RGBP	Shares Issued For Cash10 SharesIssuedForCash10	32362	usd
CY2024Q1	RGBP	Shares Issued For Cash11 SharesIssuedForCash11	25282	usd
CY2024Q1	RGBP	Shares Issued For Cash12 SharesIssuedForCash12	26781	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-122473	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-5175963	usd
CY2024Q2	RGBP	Shares Issued For Cash13 SharesIssuedForCash13	25326	usd
CY2024Q2	RGBP	Shares Issued For Cash14 SharesIssuedForCash14	13044	usd
CY2024Q2	RGBP	Shares Issued For Cash15 SharesIssuedForCash15	30000	usd
CY2024Q2	RGBP	Shares Issued For Cash16 SharesIssuedForCash16	30000	usd
CY2024Q2	RGBP	Shares Issued For Cash17 SharesIssuedForCash17	50000	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-130120	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-5157712	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-8036059	usd
CY2022Q4	RGBP	Preferred Shares Issued For Nonemployee Services PreferredSharesIssuedForNonemployeeServices	300000	usd
CY2022Q4	RGBP	Preferred Shares Issued For Debt PreferredSharesIssuedForDebt	761500	usd
CY2022Q4	RGBP	Preferred Shares Issued For Interest PreferredSharesIssuedForInterest	380262	usd
CY2022Q4	RGBP	Common Shares Issued For Interest CommonSharesIssuedForInterest	25369	usd
CY2022Q4	RGBP	Preferred Shares Issued For Nonemployee Services1 PreferredSharesIssuedForNonemployeeServices1	48372	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	1635730	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4884827	usd
CY2023Q1	RGBP	Common Shares Reverse Stock Split Value CommonSharesReverseStockSplitValue	0	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	10050	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-54978	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-4929755	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-99218	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-5028973	usd
	us-gaap	Net Income Loss NetIncomeLoss	-602353	usd
	us-gaap	Net Income Loss NetIncomeLoss	1481534	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2324	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	348372	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	13045	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-258	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	604	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	67148	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-197725	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	17383	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	43507	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2300	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-25570	usd
	RGBP	Increase Decrease In Contributed Capital IncreaseDecreaseInContributedCapital	0	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	261	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-2151755	usd
	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-110047	usd
	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-94920	usd
	RGBP	Gain Loss On Forgiveness Of Debt GainLossOnForgivenessOfDebt	-0	usd
	RGBP	Gain Loss On Forgiveness Of Debt GainLossOnForgivenessOfDebt	1150	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-204847	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-544246	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-150512	usd
	us-gaap	Proceeds From Repayments Of Other Debt ProceedsFromRepaymentsOfOtherDebt	-10000	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-40502	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	100000	usd
	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	535560	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	485058	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	100000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-59188	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-50512	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	121037	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51204	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61849	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	692	usd
	RGBP	Preferred Share Issued For Debt PreferredShareIssuedForDebt	0	usd
	RGBP	Preferred Share Issued For Debt PreferredShareIssuedForDebt	761500	usd
	RGBP	Common Shares Issued For Interests CommonSharesIssuedForInterests	0	usd
	RGBP	Common Shares Issued For Interests CommonSharesIssuedForInterests	25369	usd
	RGBP	Preferred Shares Issued For Interests PreferredSharesIssuedForInterests	0	usd
	RGBP	Preferred Shares Issued For Interests PreferredSharesIssuedForInterests	380262	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0539	pure
	RGBP	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rates ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRates	11.2835	pure
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1	pure
	us-gaap	Advertising Expense AdvertisingExpense	0	usd
	us-gaap	Advertising Expense AdvertisingExpense	0	usd
	RGBP	Net Loss NetLoss	20331216	usd
	RGBP	Non Refundable Payment Descriptions NonRefundablePaymentDescriptions	The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on July 15th, 2016 and each subsequent anniversary of the effective date of the Agreement.
CY2015Q2	us-gaap	Payments For Royalties PaymentsForRoyalties	10000	usd
CY2015Q2	us-gaap	Prepaid Royalties PrepaidRoyalties	10000	usd
CY2022Q1	us-gaap	Payments For Rent PaymentsForRent	5000	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5800000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4373078	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4373078	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4373078	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4373078	shares
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	800000000	shares
CY2024Q2	RGBP	Common Stock Share Issued CommonStockShareIssued	52763	shares
CY2024Q2	RGBP	Common Stock Value Cash Consideration CommonStockValueCashConsideration	25326	usd
CY2024Q2	RGBP	Common Stock Share Issued CommonStockShareIssued	20068	shares
CY2024Q2	RGBP	Common Stock Share Issued CommonStockShareIssued	66185	shares
CY2024Q2	RGBP	Common Stock Value Cash Consideration CommonStockValueCashConsideration	30000	usd
CY2024Q2	RGBP	Common Stock Share Issued CommonStockShareIssued	62207	shares
CY2024Q2	RGBP	Common Stock Value Cash Consideration CommonStockValueCashConsideration	30000	usd
CY2024Q2	RGBP	Common Stock Share Issued CommonStockShareIssued	75301	shares
CY2024Q2	RGBP	Common Stock Value Cash Consideration CommonStockValueCashConsideration	50000	usd

Files In Submission

Name	View Source	Status
0001607062-24-000238-index-headers.html	Edgar Link	pending
0001607062-24-000238-index.html	Edgar Link	pending
0001607062-24-000238.txt	Edgar Link	pending
0001607062-24-000238-xbrl.zip	Edgar Link	pending
ex10_1.htm	Edgar Link	pending
ex10_2.htm	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgbp-20240630.xsd	Edgar Link	pending
rgbp063024form10q.htm	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
rgbp-20240630_cal.xml	Edgar Link	unprocessable
rgbp-20240630_def.xml	Edgar Link	unprocessable
rgbp-20240630_lab.xml	Edgar Link	unprocessable
rgbp-20240630_pre.xml	Edgar Link	unprocessable
rgbp063024form10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGBP
Regen BioPharma Inc Stock $rgbp

2024 Q3 Form 10-Q Financial Statement

#000160706224000238 Filed on August 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGBP Regen BioPharma Inc Stock $rgbp

2024 Q3 Form 10-Q Financial Statement

#000160706224000238 Filed on August 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGBP
Regen BioPharma Inc Stock $rgbp